newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
biotech/news//STAT
Patients taking the targeted drug lived nearly twice as long as patients offered standard chemotherapy.
Patients on the experimental drug daraxonrasib lived almost twice as long as with standard chemotherapy.
KEY POINTS
This is the first time such survival improvement has been observed in pancreatic cancer treatment.
The clinical results for daraxonrasib were announced in April at the University of Arizona Cancer Center.
Rachna Shroff, a pancreatic cancer expert, described the findings as unprecedented in her 16-year career.
CHICAGO — Rachna Shroff, a physician and pancreatic cancer expert, was seeing patients at the University of Arizona Cancer Center in April when she heard the striking clinical results about an experimental pill called daraxonrasib. Patients taking the targeted drug lived nearly twice as long as patients offered standard chemotherapy — an outcome never seen before in the pancreatic cancer field.
“Having treated pancreatic cancer for 16 years, I actually started crying in the clinic,” Shroff said at a media briefing. “This is such an incredibly impactful study for our patients.”
Advertisement